A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas

Authors: Foley, Nicole ¹, Riedell, Peter A. ², Bartlett, Nancy L. ¹, Cashen, Amanda F. ¹, Kahl, Brad S. ¹, Fehniger, Todd A. ¹, Fischer, Anne ¹, Moreno, Chaz ¹, Liu, Jingxia ¹, Carson, Kenneth R. ^{1, 3}, Mehta-Shah, Neha ^{1, ⁎}

Source: In Clinical Lymphoma, Myeloma and Leukemia May 2025 25(5):328-336

Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium

Authors: Day, Jonathan R. ^{1, 2}, Larson, Melissa C. ³, Durani, Urshila ², Koff, Jean L. ⁴, Wang, Yucai ², Habermann, Thomas M. ², Lossos, Izidore S. ⁵, Nastoupil, Loretta J. ⁶, Strouse, Christopher ¹, Chihara, Dai ⁶, Martin, Peter ⁷, Leonard, John P. ⁷, Cohen, Jonathon B. ⁴, Kahl, Brad S. ⁸, Ruan, Jia ⁷, Burack, W. Richard ⁹, Friedberg, Jonathan W. ⁹, Cerhan, James R. ³, Flowers, Christopher R. ⁶, Link, Brian K. ¹, Maurer, Matthew J. ³, Casulo, Carla ^{9, ∗}

Source: In Blood Advances 11 March 2025 9(5):1013-1023

Improvements in Outcomes in Older Patients With Mantle Cell Lymphoma Are Associated With Improvements Across Multiple Lines of Therapy

Authors: Luan, Danny ¹, Easwar, Neela ¹, Chen, Zhengming ², Link, Brian ³, Wang, Yucai ⁴, Maurer, Matthew ⁵, Kahl, Brad ⁶, Pinheiro, Laura ⁷, Leonard, John ¹, Martin, Peter ^{1, ⁎}

Source: In Clinical Lymphoma, Myeloma and Leukemia January 2025

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial

Authors: Friedberg, Jonathan W. ^{a, ∗}, Brady, Michael T. ^a, Strawderman, Myla ^b, Kahl, Brad S. ^c, Lossos, Izidore S. ^d, Cohen, Jonathon B. ^e, Reagan, Patrick M. ^a, Casulo, Carla ^a, Averill, Barbara L. ^f, Baran, Andrea ^b, Sutamtewagul, Grerk ^g, Barr, Paul M. ^a, Leonard, John P. ^h, Ashton, John M. ^{a, i}, Strang, John G. ^j, Vega, Francisco ^k, Peterson, Derick R. ^{a, b}, Nastoupil, Loretta J. ^f

Source: In eClinicalMedicine December 2024 78

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Authors: Smith, Mitchell R., Jegede, Opeyemi A., Martin, Peter, Till, Brian G., Parekh, Samir S., Yang, David T., Hsi, Eric D., Witzig, Thomas, Dave, Sandeep, Scott, David, Hanson, Curtis, Kostakoglu Shields, Lale, Abdel-Samad, Nizar, Casulo, Carla, Bartlett, Nancy L., Caimi, Paolo F., Al Baghdadi, Tareq, Blum, Kristie A., Romer, Mark D., Inwards, David J., Lerner, Rachel E., Wagner, Lynne I., Little, Richard F., Friedberg, Jonathan W., Leonard, John P., Kahl, Brad S.

Source: In Blood 5 September 2024 144(10):1083-1092

Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation

Authors: Iqbal, Madiha, Kumar, Ambuj, Dreger, Peter, Chavez, Julio, Sauter, Craig S., Sureda, Anna M., Bachanova, Veronika, Maziarz, Richard T., Dreyling, Martin, Smith, Sonali M., Jacobson, Caron, Glass, Bertram, Casulo, Carla, Oluwole, Olalekan O., Montoto, Silvia, Advani, Ranjana, Cohen, Jonathon, Salles, Gilles, Hamad, Nada, Kuruvilla, John, Kahl, Brad S., Shadman, Mazyar, Kanate, Abraham S., Budde, Lihua Elizabeth, Kamdar, Manali, Flowers, Christopher, Hamadani, Mehdi, Kharfan-Dabaja, Mohamed A.

Source: In Transplantation and Cellular Therapy September 2024 30(9):832-843

Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL

Authors: Khurana, Arushi, Mwangi, Raphael, Nastoupil, Loretta J., Reagan, Patrick M., Farooq, Umar, Romancik, Jason T., McDonnell, Timothy J., Riska, Shaun M., Lossos, lzidore S., Kahl, Brad S., Martin, Peter, Witzig, Thomas E., Cerhan, James R., Flowers, Christopher R., Nowakowski, Grzegorz S., Maurer, Matthew J.

Source: In Blood Advances 27 August 2024 8(16):4414-4422

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma

Authors: Ramirez, Cody A., Becker-Hapak, Michelle, Singhal, Kartik, Russler-Germain, David A., Frenkel, Felix, Barnell, Erica K., McClain, Ethan D., Desai, Sweta, Schappe, Timothy, Onyeador, Onyinyechi C., Kudryashova, Olga, Belousov, Vladislav, Bagaev, Alexander, Ocheredko, Elena, Kiwala, Susanna, Hundal, Jasreet, Skidmore, Zachary L., Watkins, Marcus P., Mooney, Thomas B., Walker, Jason R., Krysiak, Kilannin, Gomez, Felicia, Fronick, Catrina C., Fulton, Robert S., Schreiber, Robert D., Mehta-Shah, Neha, Cashen, Amanda F., Kahl, Brad S., Ataullakhanov, Ravshan, Bartlett, Nancy L., Griffith, Malachi, Griffith, Obi L., Fehniger, Todd A.

Source: In Blood Advances 13 August 2024 8(15):4035-4049

Defining primary refractory large B-cell lymphoma

Authors: Bock, Allison M., Mwangi, Raphael, Wang, Yucai, Khurana, Arushi, Maurer, Matthew J., Ayers, Amy, Kahl, Brad S., Martin, Peter, Cohen, Jonathon B., Casulo, Carla, Lossos, Izidore S., Farooq, Umar, Ayyappan, Sabarish, Reicks, Tanner, Habermann, Thomas M., Witzig, Thomas E., Flowers, Christopher R., Cerhan, James R., Nastoupil, Loretta J., Nowakowski, Grzegorz S.

Source: In Blood Advances 9 July 2024 8(13):3402-3415

The Rebirth of Radioimmunotherapy of Non-Hodgkin Lymphoma: The Phoenix of Nuclear Medicine?

Authors: Wahl, Richard L., Kahl, Brad

Source: In Seminars in Nuclear Medicine July 2024 54(4):513-529

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

Authors: Batchelor, Tracy T., Giri, Sharmila, Ruppert, Amy S., Geyer, Susan M., Smith, Scott E., Mohile, Nimish, Swinnen, Lode J., Friedberg, Jonathan W., Kahl, Brad S., Bartlett, Nancy L., Hsi, Eric D., Cheson, Bruce D., Wagner-Johnston, Nina, Nayak, Lakshmi, Leonard, John P., Rubenstein, James L.

Source: In Blood Advances 25 June 2024 8(12):3189-3199

Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma

Authors: Ghobadi, Armin, Foley, Nicole C., Cohen, Jared, Rettig, Michael P., Cashen, Amanda F., Gehrs, Leah, Christ, Stephanie, Street, Emily, Wallace, Nicholas, Ritchey, Julie, Mehta-Shah, Neha, Westervelt, Peter, Fehniger, Todd A., Kahl, Brad, Bartlett, Nancy L., DiPersio, John F.

Source: In Blood Advances 13 February 2024 8(3):513-522

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era

Authors: Desai, Sanjal H., Spinner, Michael A, Evens, Andrew M., Sykorova, Alice, Bachanova, Veronika, Goyal, Gaurav, Kahl, Brad, Dorritie, Kathleen, Azzi, Jacues, Kenkre, Vaishalee P., Chang, Cheryl, Michalka, Jozef, Ansell, Stephen M., Fusco, Brendon, Sumransub, Nuttavut, Hatic, Haris, Saba, Raya, Ibrahim, Uroosa, Harris, Elyse I., Shah, Harsh, Wagner-Johnston, Nina, Arai, Sally, Nowakowski, Grzegorz S., Mocikova, Heidi, Jagadeesh, Deepa, Blum, Kristie A., Diefenbach, Catherine, Iyengar, Siddharth, Rappazzo, K. C., Baidoun, Firas, Choi, Yun, Prochazka, Vit, Advani, Ranjana H., Micallef, Ivana

Source: In Blood Advances 12 December 2023 7(23):7295-7303

Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma

Authors: Nastoupil, Loretta J. ^{1, ⁎}, Andersen, Clark R. ¹, Ayers, Amy ¹, Wang, Yucai ², Habermann, Thomas M. ², Chihara, Dai ¹, Kahl, Brad S. ³, Link, Brian K. ⁴, Koff, Jean L. ⁵, Cohen, Jonathon B. ⁵, Martin, Peter ⁶, Lossos, Izidore S. ⁷, Stanchina, Michele ⁷, Haddadi, Sara ⁸, Casulo, Carla ⁹, Ayyappan, Sabarish ⁴, Lin, Ruitao ¹³, Li, Ziyi ¹³, Larson, Melissa A. ¹⁴, Maurer, Matthew J. ¹⁴, Huynh, Lynn ¹², Gao, Chi ¹², Ramasubramanian, Ramya ¹², Duh, Mei Sheng ¹², Mutebi, Alex ¹⁰, Wang, Tongsheng ¹⁰, Jun, Monika ¹⁰, Wang, Anthony ¹¹, Kamalakar, Rajesh ¹¹, Kalsekar, Anupama ¹⁰, Cerhan, James R. ¹⁵, Flowers, Christopher R. ¹

Source: In Clinical Lymphoma, Myeloma and Leukemia April 2025 25(4):e183-e199

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303

Authors: Russler-Germain, David A., Krysiak, Kilannin, Ramirez, Cody, Mosior, Matthew, Watkins, Marcus P., Gomez, Felicia, Skidmore, Zachary L., Trani, Lee, Gao, Feng, Geyer, Susan, Cashen, Amanda F., Mehta-Shah, Neha, Kahl, Brad S., Bartlett, Nancy L., Alderuccio, Juan P., Lossos, Izidore S., Ondrejka, Sarah L., Hsi, Eric D., Martin, Peter, Leonard, John P., Griffith, Malachi, Griffith, Obi L., Fehniger, Todd A.

Source: In Blood Advances 26 September 2023 7(18):5524-5539

SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma

Authors: Patel, Dilan, Kahl, Brad

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23(9):633-641

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma

Authors: Sawalha, Yazeed, Goyal, Subir, Switchenko, Jeffrey M., Romancik, Jason T., Kamdar, Manali, Greenwell, I. Brian, Hess, Brian T., Isaac, Krista M., Portell, Craig A., Mejia Garcia, Alex, Goldsmith, Scott, Grover, Natalie S., Riedell, Peter A., Karmali, Reem, Burkart, Madelyn, Buege, Michael, Akhtar, Othman, Torka, Pallawi, Kumar, Anita, Hill, Brian T., Kahl, Brad S., Cohen, Jonathon B.

Source: In Blood Advances 11 July 2023 7(13):2983-2993

Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies

Authors: Patel, Dilan A., Wan, Fei, Trinkaus, Kathryn, Guy, Daniel G., Edwin, Natasha, Watkins, Marcus, Bartlett, Nancy L., Cashen, Amanda, Fehniger, Todd A., Ghobadi, Armin, Shah, Neha-Mehta, Kahl, Brad S.

Source: In Clinical Lymphoma, Myeloma and Leukemia July 2023 23(7):552-560

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Authors: Epperla, Narendranath ^∗, Switchenko, Jeffrey, Bachanova, Veronika, Gerson, James N., Barta, Stefan K., Gordon, Max J., Danilov, Alexey V., Grover, Natalie S., Mathews, Stephanie, Burkart, Madelyn, Karmali, Reem, Sawalha, Yazeed, Hill, Brian T., Ghosh, Nilanjan, Park, Steven I., Bond, David A., Hamadani, Mehdi, Fenske, Timothy S., Martin, Peter, Malecek, Mary-Kate, Kahl, Brad S., Flowers, Christopher R., Link, Brian K., Kaplan, Lawrence D., Inwards, David J., Feldman, Andrew L., Hsi, Eric D., Maddocks, Kami, Blum, Kristie A., Bartlett, Nancy L., Cerhan, James R., Leonard, John P., Habermann, Thomas M., Maurer, Matthew J., Cohen, Jonathon B.

Source: In Blood Advances 13 June 2023 7(11):2287-2296

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Authors: Campo, Elias ^*, Jaffe, Elaine S. ^*, Cook, James R., Quintanilla-Martinez, Leticia, Swerdlow, Steven H., Anderson, Kenneth C., Brousset, Pierre, Cerroni, Lorenzo, de Leval, Laurence, Dirnhofer, Stefan, Dogan, Ahmet, Feldman, Andrew L., Fend, Falko, Friedberg, Jonathan W., Gaulard, Philippe, Ghia, Paolo, Horwitz, Steven M., King, Rebecca L., Salles, Gilles, San-Miguel, Jesus, Seymour, John F., Treon, Steven P., Vose, Julie M., Zucca, Emanuele, Advani, Ranjana, Ansell, Stephen, Au, Wing-Yan, Barrionuevo, Carlos, Bergsagel, Leif, Chan, Wing C., Cohen, Jeffrey I., d'Amore, Francesco, Davies, Andrew, Falini, Brunangelo, Ghobrial, Irene M., Goodlad, John R., Gribben, John G., Hsi, Eric D., Kahl, Brad S., Kim, Won-Seog, Kumar, Shaji, LaCasce, Ann S., Laurent, Camille, Lenz, Georg, Leonard, John P., Link, Michael P., Lopez-Guillermo, Armando, Mateos, Maria Victoria, Macintyre, Elizabeth, Melnick, Ari M., Morschhauser, Franck, Nakamura, Shigeo, Narbaitz, Marina, Pavlovsky, Astrid, Pileri, Stefano A., Piris, Miguel, Pro, Barbara, Rajkumar, Vincent, Rosen, Steven T., Sander, Birgitta, Sehn, Laurie, Shipp, Margaret A., Smith, Sonali M., Staudt, Louis M., Thieblemont, Catherine, Tousseyn, Thomas, Wilson, Wyndham H., Yoshino, Tadashi, Zinzani, Pier-Luigi, Dreyling, Martin, Scott, David W., Winter, Jane N., Zelenetz, Andrew D.

Source: In Blood 15 September 2022 140(11):1229-1253